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Somatic genetic aberrations in benign breast disease
and the risk of subsequent breast cancer
Zexian Zeng1,2, Andy Vo3, Xiaoyu Li 4, Ali Shidfar5, Paulette Saldana5, Luis Blanco6, Xiaoling Xuei7, Yuan Luo 1✉,
Seema A. Khan5✉ and Susan E. Clare 5✉
It is largely unknown how the development of breast cancer (BC) is transduced by somatic genetic alterations in the benign breast.
Since benign breast disease is an established risk factor for BC, we established a case-control study of women with a history of
benign breast biopsy (BBB). Cases developed BC at least one year after BBB and controls did not develop BC over an average of 17
years following BBB. 135 cases were matched to 69 controls by age and type of benign change: non-proliferative or proliferation
without atypia (PDWA). Whole-exome sequencing (WES) was performed for the BBB. Germline DNA (available from n= 26
participants) was utilized to develop a mutation-calling pipeline, to allow differentiation of somatic from germline variants. Among
the 204 subjects, two known mutational signatures were identified, along with a currently uncatalogued signature that was
significantly associated with triple negative BC (TNBC) (p= 0.007). The uncatalogued mutational signature was validated in 109
TNBCs from TCGA (p= 0.001). Compared to non-proliferative samples, PDWA harbors more abundant mutations at PIK3CA pH1047R
(p < 0.001). Among the 26 BBB whose somatic copy number variation could be assessed, deletion of MLH3 is significantly associated
with the mismatch repair mutational signature (p < 0.001). Matched BBB-cancer pairs were available for ten cases; several mutations
were shared between BBB and cancers. This initial study of WES of BBB shows its potential for the identification of genetic
alterations that portend breast oncogenesis. In future larger studies, robust personalized breast cancer risk indicators leading to
novel interception paradigms can be assessed.
npj Breast Cancer            (2020) 6:24 ; https://doi.org/10.1038/s41523-020-0165-z
INTRODUCTION
From 1989 to 2016 the mortality rate for breast cancer (BC) in the
United States decreased by 40%1, a testament to the efficacy of
targeted therapies, as well as to combinations and schedules of
chemotherapeutics. During this same period breast cancer
incidence rates remained static1; evidence of both the paucity of
novel, effective prevention strategies that target specific mole-
cular risk pathways, and our inability to implement existing
strategies. Major barriers are two-fold: hesitation among healthy
women to accept drugs for a disease that they may or may not
experience in the future; and their reluctance to experience side
effects that impair quality of life and may compromise health2.
The first of these would be mitigated by improved identification of
women at high risk of developing breast cancer, but almost 30
years after the initial publication of the Gail Model3, breast cancer
risk stratification remains imprecise and insensitive to breast
cancer subtype. In an analysis of data from the Women’s Health
Initiative, the Gail Model displayed modest ability to predict the
risk of breast cancer (AUC= 0.58, 95% CI= 0.56–0.60)4. Among
women at high risk of breast cancer, for example, those diagnosed
with atypical hyperplasia, neither the Gail Model/Breast Cancer
Risk Assessment Tool nor the Tyrer-Cuzick Model performed
well5,6. This is a significant barrier to implementation of
established medical interventions for disease prevention, and to
the development of new, targeted intervention strategies for
women at risk. Impactful, targeted prevention strategies require
knowledge of how breast cancer risk is transduced at the
molecular level in the breast itself, i.e., identification of somatic
genetic changes that predate breast cancer and influence the
biologic profile of cancers that emerge.
Benign breast disease is an established risk factor for BC7,8, with
30% of BC cases reporting a history of benign breast disease9. Of
the 1.7 million breast biopsies each year in the U.S.10, about 75%
of these return a diagnosis of benign breast disease, including
atypical hyperplasia9. This provides a window into the somatic
genetic environment of the breast, prompting us to evaluate the
genetic landscape of benign breast biopsy (BBB), and identify
patterns associated with subsequent malignancy. Starting in the
embryo11, tissues accumulate DNA mutations over time12. Most of
the mutations are repaired, many are inconsequential, but a few
may lead to cancer13,14. Before there is any histologic evidence of
invasive cancer, histologically normal, and benign tissue contain
molecular aberrations that are associated with malignancy15,16.
For example, sun-exposed, normal eyelid skin has been shown to
have a mutation burden of 2–6 mutations/MB/cell, a rate similar to
that observed in many cancers17. The processes that cause these
mutations leave an imprint on the genome18. In the sun-exposed
eyelid epidermis, mutations occur within a pattern that mimics the
Welcome Trust Sanger Institute (WTSI) Mutation Signature, which
is associated with ultraviolet exposure and its consequent CC > TT
dinucleotide mutations at dipyrimidines19. Exogenous or endo-
genous mutational processes, such as that which produced WTSI
signature 7, are chemical reactions within DNA. While mutational
processes are responsible for the creation of mutations, the
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mutations that are observed ultimately within a malignancy reflect
a process of selection20. However, genetic aberrations are not
limited to somatic mutations, and we note that recurrent copy
number variations (CNVs) are in fact more characteristic of
invasive breast cancers than recurrent mutations20.
To evaluate the molecular alterations that enable cancer
development in the breast, we established a case-control study
of BBB samples, the Benign Breast & Cancer Risk (BBCAR) Study.
We performed whole-exome sequencing (WES) on the benign
biopsies of patients, who subsequently developed breast cancer
(cases), and matched controls, who have not developed breast
cancer to date. The cases and controls had similar degrees of
benign change: non-proliferative or proliferation without atypia.
The focus on non-atypical lesions was a deliberate choice as non-
atypical lesions predict a generalized risk of subsequent breast
cancer, occurring equally frequently in both breasts9. They are also
far more common than atypical changes, comprising over 90% of
all breast biopsies21, so that elucidation of their molecular profiles
will impact the majority of women who undergo BBB. To the best
of our knowledge, WES has not been performed in any previous
case-control study of benign breast lesions without atypia. In
addition to profiling the overall BBB mutational landscape, we
have determined that mutations differ as a function of the type of
benign breast disease, specifically that the PIK3CA pH1047R
hotspot mutation is more frequent in proliferative disease without
atypia (PDWA) compared to non-proliferative disease (p < 0.001);
our data reveals a presently uncatalogued mutational signature
associated with TNBC (p= 0.007), which was validated in 109
TCGA TNBC samples (p= 0.001); and we observed multiple
recurrent CNVs, including a MLH3 deletion, which is significantly
associated with a mismatch repair signature (p < 0.001).
RESULTS
Study design
A total of 204 subjects were enrolled in this BBB case-control
study. Cases (n= 135) are women who have undergone a breast
biopsy with specimen histology showing non-proliferative disease
or proliferative disease without atypia (Supplementary Fig. 1) that
predates the diagnosis of breast cancer by at least one year (Fig.
1a). The median interval from benign biopsy to the diagnosis of
cancer is 7.3 (SD= 4.4) years. Controls (n= 69) are women who
have not developed breast cancer and are matched for age of
diagnosis (±2 years) and histology (Fig. 1b; Table 1). Controls were
verified to not have been diagnosed with breast cancer as of 08/
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Fig. 1 Case-control study of benign breast biopsy (BBB) samples. a Design of the BBCAR study. The sample tissues of subjects who
subsequently developed breast cancer (cases), and their matched controls, who have not developed breast cancer to date, were studied b A
total of 135 cases, matched to 69 controls, were selected for whole-exome sequencing (WES). Case and control samples are matched by age
and histology c. an illustration of the workflow to identify somatic mutations in the tissue samples that lack matched germline DNA. To train a
model to distinguish germline variants and somatic mutations, previously consented donors were re-contacted (with IRB approval) and saliva
specimens were requested for germline DNA sequencing. Orthogonal SNP array genotyping was further performed with 20 samples to
compare and validate the performance of somatic mutation identification.
Table 1. Distributions of demographic data and tumor characteristics
between the Case group and the Control group Student’s t-tests were
performed for continuous variables and Pearson’s Chi-squared tests
were performed for categorical variables.
Case (135) Control (69) P-value
Age (SD) Mean (SD) 49.7 (9.9) 49.8 (9.6) 0.96
Menopausal status N (%) 0.87
Pre 114 76 (56.3%) 38 (55.1%)
Post 90 59 (43.7%) 31 (44.9%)
Histology Class N (%) 0.78
aClass 1 115 79 (58.5%) 40 (58.0%)
bClass 2 75 51 (37.8%) 25 (36.2%)
NA 10 5 (3.7%) 4 (5.8%)




Follow-up years (SD) 7.3 (4.4) 16.6 (5.4) <0.01
Has matched germline (%) 20 (14.8%) 6 (8.7%)
Has matched cancer (%) 10 (7.4%)
aClass 1/non-proliferative: “Non-proliferation” and “Benign, NOS”.
bClass 2/proliferative: “Proliferative lesion without atypia” (includes non-
atypical hyperplasia, radial scar, sclerosing adenosis).
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All 204 specimens were dissected using laser capture microdissec-
tion (LCM) and were subjected to WES23. Within this cohort, 26
matched germline DNA were obtained for WES as well. To
evaluate mutation caller performance in this benign tissue setting,
17 of the 26 sample pairs were subjected to genotyping in order
to evaluate mutation caller performance (Fig. 1c; “Methods”,
“Supplementary Materials and Methods”). Allele frequencies of the
mutations common to the genotyping array and WES were
compared. Mutations were categorized as false positive if allele
frequency was discrepant between the two platforms. The
mutation identification accuracy then varies as a function of the
discrepancy allowance (Fig. 2a). Overall, we observed high
consistency between the two platforms (85.4% when discrepancy
allowance= 25%). Notably, MuTect2 consistently achieved better
performances in this setting (Fig. 2a), Therefore, MuTect2 was
selected as mutation caller for subsequent studies.
For the samples lacking matched normal DNA (n= 178), a
machine learning model was developed to distinguish germline
variants and somatic mutations (Fig. 1c; “Methods”; “Supplemen-
tary Materials and Methods”). With somatic mutations called for
the 26 samples for which germline DNA was available, we
systematically evaluated multiple machine learning approaches to
distinguish somatic mutations and germline variants in benign
biopsies (Fig. 1c; “Methods”; “Supplementary Materials and
Methods”). A total of 31 features were utilized for the model
evaluation (Supplementary Table 1), including protein structure,
pathogenicity prediction, population frequency, or evolutionary
factors24. Various functional annotation or toxicity scores were
derived from ANNOVAR25, COSMIC (https://cancer.sanger.ac.uk/
cosmic), dbSNP/common (https://www.ncbi.nlm.nih.gov), along
with intrinsic sequencing features, such as mutation allele
frequency, depth of reference reads, mutation frequency among
the cohort. Grid search was applied to unbiasedly tune each
model’s parameters using five-fold cross-validation on the training
set. Evaluation performance was then achieved on the held-out
test set (“Methods”). Of the evaluated models including penalized
logistic regression (LR), linear SVM, random forest classifier (RFC),
gradient boosted tree (GBT), k-nearest neighbor algorithm (K-NN),
SVM with rbf kernel, and multi-layer perceptron (MLP), MLP model
achieved the best performance (Fig. 2b), where the F1-score is
0.96 (Supplementary Table 2).
Orthogonal validations of the proposed model were performed
by evaluation studies with the TCGA data and benchmark studies
with previously validated pipelines. Protected datasets in bam
format of 100 randomly selected breast primary tumors were
downloaded directly from the TCGA data portal. Realigned raw
reads were subjected to base recalibration and were passed to
Mutect2 for mutation detection. Mutect2 was performed in so
called “tumor only mode” to call somatic and germline mutations.
ISOWN26, a previously validated pipeline for somatic mutation
identification, was applied for somatic mutation prediction as well.
The predicted results were evaluated by comparison to the TCGA
somatic mutation data by Multi-Center Mutation-Calling in Multi-
ple Cancers (MC3 public v0.2.8) network27. Using the TCGA MC3
data as ground truth, our model achieved a F1-score of 0.89 (Fig.
2c) in predicting somatic mutations. Even though designed and
trained in the benign-biopsy setting, our model (F1= 0.89)
obtained similar or better results than previously validated
pipelines, such as ISOWN NBC (F1= 0.88) and ISOWN LAD tree26
(F1= 0.80) in predicting somatic mutations in TCGA cancer
samples (Fig. 2c).
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Fig. 2 Accurate somatic mutation identification in benign biopsies. a Comparison of the mutations between WES and genotype array.
Somatic mutations were called using Mutect2, VarScan2, and VarDict. With different allele frequency discrepancy allowance, the overlap rate
between two platforms was plotted. b Performance of different machine learning models in the test set. Penalized logistic regression (LR);
linear SVM; random forest classifier (RFC); gradient boosted tree (GBT); k-nearest neighbor algorithm (K-NN); SVM with rbf kernel; multiple
layer perceptron (MLP). c Orthogonal validation of the proposed model using 100 TCGA breast cancer samples and benchmark study with
previously validated pipelines, including ISOWN NBC and ISONWN LAD tree26. d Pipeline validation using genotype arrays of three samples.
Somatic mutations were called using our pipeline and validated by genotyping. The plot shows the overlap rate between the two platforms
with different allele frequency discrepancy allowance. e VAF distribution of the germline variants and somatic mutations, grouped by 26
benign biopsies with matched normal DNA, 178 benign biopsies lacking matched normal DNA, and 100 randomly selected TCGA breast
cancer samples. f Distribution of silent and non-silent mutations, grouped by germline variants called in normal DNA that matched to the BBB,
somatic mutations in BBB, and somatic mutations in TCGA breast cancer samples.
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We further applied our pipeline and model to identify somatic
mutations in the 178 BBBs lacking matched normal DNA (Fig. 1c)
(Methods). Overall, the average read depth for the identified
somatic mutations is 99, whereas the average VAF is 0.232. To
estimate the overall mutation identification accuracy, we ran-
domly sampled and genotyped three samples from our cohort.
Overall, we observed high consistency between our pipeline and
the genotype array (82.5% when discrepancy allowance= 25%)
(Fig. 2d). As a sanity check, the distribution of variant allele
frequency (VAF) and non-silent mutations were examined.
Consistent with previously reported studies28,29, the majority of
our identified germline variants’ VAFs are around 50% and 100%,
whereas somatic mutations display much lower VAFs (Fig. 2e). For
cancers, non-silent mutations usually account for 2/3 of somatic
mutations with the remaining 1/3 being silent mutations, whereas
germline mutations are expected to have higher number of silent
mutations28. In our data, we have observed similar distribution
(TCGA 100 breast cancer: 72% non-silent mutations) (Fig. 2f). In
addition, we observed an increasing spectrum of non-silent
mutations in BBB matched normal DNA (32%), BBB (63%), and
TCGA cancer samples (72%) (Fig. 2f). To note, the average non-
synonymous mutations for the 26 BBBs with matched normal DNA
is 114, whereas the average number for the 178 BBBs without
matched normal DNA is 127.
Mutation catalogues
Among the 204 samples, 36,801 somatic base substitutions and
2283 small INDELs were identified. The majority of the mutations
were missense mutations (Fig. 3a). Cases had a mean of 6.2
mutations/MB (SD= 3.6) and controls had 6.8 mutations/MB (SD
= 3.0). No significant difference was observed in the numbers of
mutations between the cases and controls (Fig. 3a). Among the
top 20 mutated genes, the case group and control group shared
common genes (MUC17, OBSCN, FLG2, GLTPD2, ABCA13, PIK3CA)
(Fig. 3b). Approximately one-fifth of both cases and controls
display PIK3CA mutations, with the highest frequency at pH1047R.
When corrected by gene length, case and control still shared
common genes (MUC17, SLC7A4, FLG2, GLTPD2, PGBD1, PLA2G3,
ADAM30) (Fig. 3c). Mucins are O-glycosylated by the addition of N-
acetylgalactosamine to the hydroxyl group of serine or threo-
nine30. Therefore, we evaluated the number of missense muta-
tions within MUC17 that resulted in the gain or loss of either
serine or threonine residues. Of the MUC17 mutations we
observed, 8.7% of missense mutations would be predicted to
result in the loss of serine, 16.8% in the loss of threonine, 14.2% in
the gain of serine and 17.8% in the gain of threonine. However,
there was no significant difference between cases and controls
(Supplementary Table 3). The proportions of nonsense mutations
also vary between samples. The majority of nonsense mutations
were frame shift insertions and stop gains, with some exceptions
in a few samples (Fig. 3d).
Genes enriched for mutations in the cases or PDWA
To determine the enrichment of mutations in the case group, a
logistic regression model was fit for each gene, with case/control
as output variable and mutation status as input variables. The p-
values were derived from the fitted models for gene sorting (Fig.
4a). Nonsynonymous mutations in four cancer-associated genes,
CTNNA2 (11.1% vs. 5.8%; log10 p-value=−0.6), FLG (8.9% vs. 4.3%;
log10 p-value=−0.6), GNAS (4.4% vs. 1.4%; log10 p-value=−0.5),
and BCORL1 (17.0% vs. 11.6%; log10 p-value=−0.5), were more
abundant in the case group. Of note, same analyses including
synonymous mutations are presented in Supplementary Fig. 2.
Rohan and colleagues utilized targeted sequence capture to
identify mutations present in a panel of 83 genes in the benign
breast disease tissue from a case-control study31. While they
identified somatic mutations in a number of genes frequently
mutated in breast cancer, no significant differences were
identified comparing cases and controls with regard to the
mutational burden, genes mutated, type of mutation or pathway.
We queried our data for the mutations present in these same 83
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Fig. 3 Catalog of somatic mutations in 204 benign breast biopsies. a Catalog of base substitutions, insertions/deletions in the 204 BBBs.
Each bar represents one individual’s total number of mutations. Left panel is the case and right panel is the control. b The top 20 mutated
genes in the case group (left) and control group (right). c The top mutated genes as b, adjusted by gene length. d Catalog of nonsense
mutations in the 204 BBBs.
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which orthogonally validated our data quality. Nonetheless,
differences were observed after filtering for variants with a VAF >
25%; in particular, while no variants in NCOA3 had a VAF greater
than 25% in the controls, over 10% of cases passed this threshold
(Fig. 4b).
We also evaluated mutation enrichments in benign biopsies
showing proliferative disease without atypia (PDWA) (n= 76)
versus non-proliferate (NP) disease (n= 119). Using non-
synonymous mutations only, the top enriched significant genes
are PIK3CA, HYDIN, DNMT3B, and AKT1 (detail of hotspots in
Supplementary data 2)22. For PIK3CA, mutations are abundantly
enriched in PDWA compared to NP (31% vs. 12%; p= 0.00001)
(Fig. 4c). Specifically, pH1047R is the most enriched hotspot for the
PDWA (28% vs. 5%; p < 0.00001) (Fig. 4d)
Mutational processes and CNV
Mutations are non-random and occur within sequence motifs.
These motifs provide evidence from which we can infer the
process that created the mutations. Recent studies led by
investigators at the Welcome Trust Sanger Institute (WTSI) present
the somatic mutation data as a 96-element vector, which captures
the immediate 5′ and 3′ neighbors of the mutated nucleotides.
Employing non-negative matrix factorization (NMF), 30 “muta-
tional signatures” were produced by these studies19,32, which
more recently has been updated and expanded to 4033. We
hypothesized that like the eyelid epidermis17, benign breast
lesions also harbor somatic mutations with associated mutational
signatures that may provide clues to etiologic processes. Within
the BBB cohort, mutational signatures were examined. Three
mutational signatures were identified in both case and control
group (Supplementary data 3)22. In both groups, we identified the
“aging” signature (cataloged by WTSI as Signature 1b; Fig. 5a;
cosine similarity score: 83.2% for the case and 83.0% for the
control), which is the putative result of the hydrolysis 5-
methylcytosine. We also identified the “mismatch repair” signature
(cataloged by WTSI as Signature 6; Fig. 5a; cosine similarity score:
80.5% for the case and 80.1% for the control). Moreover, a
signature not currently in the WTSI catalog of Mutational
Signatures was identified in each group; both demonstrate
enrichment of T > G mutations with 5′TTC3′ > 5′TGC3′ the most
frequently mutated trinucleotide motif (Fig. 5a). Provisionally, we
have named this signature “O/TN” based on the presumed
mechanism: oxidation, and on its presumptive association with
triple negative (TN) breast cancer.
The process of deriving mutational signatures is an unsuper-
vised learning process. Pooling the cases and controls, we derived
three signatures in the BBB cohort, namely aging, mismatch repair,
and O/TN. In an association study, we found that O/TN was
significantly associated with BBB that predate TNBC (p= 0.007)
(Fig. 5c). We also performed a second association analysis,
controlling for the potential covariates of age, menopausal status,
and histology class (NP or PDWA). The association remained
significant (p= 0.016), suggesting that the O/TN signature in BBB
is predictive of TNBC. To validate the O/TN signature and examine
whether it is a predictor of TNBC as well, we further retrieved 109
TNBC samples from TCGA data portal. The downloaded somatic
mutation data were processed, and three mutational signatures










DMD 11.9 2.9 -1.3
TSKS 12.6 4.3 -1.1
ZNF559 8.9 2.9 -0.9
DENND2C 6.7 1.4 -0.9
TENM4 6.7 1.4 -0.9
PAQR5 6.7 1.4 -0.9
BEST3 6.7 1.4 -0.9
AHNAK 28.1 18.8 -0.8
RGSL1 10.4 4.3 -0.8
NLGN4X 8.1 2.9 -0.8
MYO15B 5.9 1.4 -0.8
APOB 7.4 2.9 -0.7
HTT 5.2 1.4 -0.7
ZNF423 5.2 1.4 -0.7
HECTD4 5.2 1.4 -0.7
PLXNA1 5.2 1.4 -0.7
PTPRS 5.2 1.4 -0.7
TTC14 5.2 1.4 -0.7
CTNNA2 11.1 5.8 -0.6
FLG 8.9 4.3 -0.6
MAGI3 12.6 7.2 -0.6
RPGRIP1 14.1 8.7 -0.6
SHCBP1L 6.7 2.9 -0.6
PHRF1 10.4 5.8 -0.5
PLXDC1 10.4 5.8 -0.5
KIF6 4.4 1.4 -0.5
MAMDC4 4.4 1.4 -0.5
DDX42 4.4 1.4 -0.5
DUS1L 4.4 1.4 -0.5
4.4 1.4 -0.5
THNSL1 4.4 1.4 -0.5
ZNF595 4.4 1.4 -0.5
4.4 1.4 -0.5
FAM209B 4.4 1.4 -0.5
LRP1 4.4 1.4 -0.5
TOPORS 4.4 1.4 -0.5
TRIO 4.4 1.4 -0.5
ZNF627 4.4 1.4 -0.5
BCORL1 17.0 11.6 -0.5
TMC6 11.9 7.2 -0.5
RYR2 8.1 4.3 -0.5
DIDO1 8.1 4.3 -0.5
MUC5B 20.0 14.5 -0.5
GNAS
ZNF782
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Fig. 4 Genetic aberrations that distinguish case/control or proliferative/non-proliferative BBB. a For each gene, the percentage of mutated
lesions in the case and control are shown. In the left panel, known oncogenes are highlighted as green, and known tumor suppressor genes are
highlighted as orange. Onc is a known oncogene; TS is a tumor suppressor gene (Cancer Gene Census; https://cancer.sanger.ac.uk/census). The
right panel shows the nonsynonymous rate in each group. bMutations in 83 selected genes presented by Rohan et al.31 to validate our data and
also to facilitate comparisons. Left: all non-silent mutations; right: non-silent mutations with VAF > 25%. c PIK3CA non-synonymous mutations
identified in NP BBB and PDWA BBB. d Same as c, with only mutations at PIK3CA pH1047R retained.
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we were able to identify the O/TN signature in the TCGA TNBC
cohort (Cosine= 0.72, p= 0.001).
A majority of breast tumors, especially those that are HER2
positive, have been reported to be enriched with mutations
hypothesized to result from the action of the APOBEC enzymes34.
In our cohort, no tumors were found to be enriched with
mutations within the APOBEC motif, nor did we observe either
WTSI Signatures 2 or 13, both of which are hypothesized to be the
result of the activity of these enzymes. We have also examined the
subset of 11 BBB that eventually developed HER2 positive cancer
and the subset of 29 BBB that developed cancer within 3 years of
biopsy, and we found no APOBEC signatures enriched in
these BBB.
We also employed VarScan235 to study somatic CNV in the
26 samples for which we have matched normal DNA. The learnt
segments were then passed to GISTIC236 for recurrent CNVs study
(genome-wide CNV variation: Supplementary Fig. 3). We observed
that majority of the cytobands occur at or immediately next to
common fragile sites, suggesting these cells are under consider-
able replication stress (Fig. 5b). The observed cytobands at which
CNVs map exclusively in the cases have been associated with
cancers, in general or invasive breast cancers, in particular.
Amplifications are hypothesized to be the result of breakage-
fusion-bridge (BFB) cycles triggered at the induction of fragile
sites37. One of the amplifications identified in the BBCAR cases is
an amplification outlier identified using breast cancers from the
METABRIC consortium that mapped to chr19q13.33, which
contains 26 genes. No candidate oncogene has yet to be
identified within this amplicon38. Chromosome 1q21 is the fourth
most frequent locus of copy number variations in cancer39.
To investigate the mechanisms underlying our mismatch repair
signature, mismatch repair genes MLH1, MLH3, MSH2, MSH3,
MSH6, PMS2, MUTYH, MYH11, SETD2 and TGFBR were examined for
deleterious mutations and/or deletion in the subset of samples
with matched germline DNA available (N= 26)40. Approximately
one-third of the cases and controls have at least one mutation in
one of the mismatch repair associated genes (Supplementary
data 4)22. PMS2 is deleted in one-half of the cases (10/20) and
MLH3 in all of the controls (6/6). However, only one of the 10 cases
displaying a PMS2 deletion also evidenced a mutation in an MMR
associated gene, specifically SETD2. None of the controls with
MLH3 deletions carried a mutation in any of the MMR associated
genes. Strikingly, benign biopsies harboring a MLH3 deletion are
abundantly enriched with the mismatch repair signature com-
pared to MLH3 wild biopsies (p= 4.2E-6) (Fig. 5d).
Cancer risk prediction at BBB
In an attempt to build a model for cancer prediction at the time of
BBB using somatic information, we fit logistic regression with L1
penalty using the case/control status as output variable. To reduce
the number of input prediction features, all somatic mutations
that were annotated with same protein domain were aggregated
as a continuous number, representing the mutation burden of the
corresponding protein domain. In total, 1966 annotated protein
domains were utilized as input features for case/control prediction
(Supplementary data 5)22. To evaluate the model and features, we
performed a bootstrapping by randomly splitting the BBB samples
at a 7:3 ratio, and trained the model using 70% of the samples, in
which 30% of the samples were used as test set. We repeated the
process ten times and obtained an AUC for each run. As a result,
we obtained an AUC score of 67% (95% CI= 63.1–70.9%) in
predicting the cases. Of note, the inclusion of clinical character-
istics and demographics, including age at the time of BBB, age at
menarche, age at first live birth, family history of breast cancer in a
first-degree relative, histologic variable (proliferative vs non-
proliferative), did not improve the model’s performance.
Somatic mutations present in both benign biopsy and cancer
Our cases were defined as BBB that predate breast cancer. In this
study, to longitudinally compare mutations in the BBB and in the
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Fig. 5 Mutational processes and somatic copy number variation (CNV) identified in the case and control groups. a The identified mutation
signatures were compared with those of the Welcome Trust Sanger Institute. The aging signature and mismatch repair signature (MMR) are
enriched in both groups. The uncatalogued signature O/TN is enriched with T > G/A > C mutations, with 5′GAA3′ > 5′GCA3′ the most
frequently mutated trinucleotide. b Recurrent somatic copy number variation in the case group. Common fragile sites are labeled. The size of
the dots represents the q-value (FDR adjusted p-value). Red are amplifications, blue are deletions. y-axis is the number of genes involved, and
x-axis is the number of samples involved. c The uncatalogued signature is enriched in BBBs that predate triple negative breast cancer. Each
sample is assigned a continuous number representing the signature exposure strength, which was the product of matrix decomposition.
d The mismatch repair signature is highly abundant in the BBB with MLH3 deletion (MLH3 naive). Error bars are 95% confidence interval (CI).
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cohort. Preprocessing for mutation calling was performed as for
the BBB, including laser capture microdissection (LCM), DNA
extraction, library construction, sequencing, alignment, mutation
calling, and variant filtering. Of the identified mutations in these
ten cancer samples, 957 were observed in both the benign
biopsies and cancer tissues (Supplementary data 6)22. The average
allele frequencies for these mutations is 32.2% (SD= 18.7%) in the
BBB and 46.7% (SD= 17.3%) in the cancer tissues. FAT1, CTNNA2,
ATR and ETAA1 were among the top ten mutated genes
(Supplementary Table 4); these are known tumor suppressor
genes or oncogenes. All six of the CTNNA2 mutations occur within
the motif 5′GAA3′ > 5′GCA3′. This motif is a predominant feature
of our O/TN mutation signature (Fig. 3).
DISCUSSION
Genetic aberrations associated with malignancy occur within
normal tissues17 and within tissues at the population risk of breast
cancer15 as well as within lesions at substantial risk16. A previous
case-control study performed by Rohan et al., with a design that
closely mirrors ours, utilized targeted sequence capture31; no
significant differences between cases and controls with regard to
somatic mutations were identified and no mutations were shared
between the biopsy and tumor pairs. Comparing the number of
somatic mutations identified in their targeted genes with these
same genes in our WES data revealed striking similarity and to
make the similarity easy to discern, we designed Fig. 4b to mirror
their Fig. 1a, b. Soysal and colleagues also employed targeted
sequencing in an attempt to identify somatic mutations present in
antecedent fibrocystic disease (FD) and subsequent invasive
breast cancers41. In contrast to our study and that of Rohan
et al.31, no significant somatic mutations were identified in the FD.
In their discussion section Rohan et al. suggested that “more
detailed approaches (e.g., exome/whole-genome sequencing)”
might prove more informative than targeted sequencing31. We
employed WES in a similar case-control setting. We rigorously
evaluated the sequencing quality, mutation calling, and mutation
classification. Since we did not have germline samples available
from most of our subjects, we developed a neural network model
to predict somatic mutations for the benign biopsies, which we
were able to accomplish with a F1 score of 96%. This tool was
further validated in TCGA (MC3) data with a F1 score of 89%. Using
the sequencing data produced, we have identified recurrent
mutated genes. We also built a predictive model for the risk of
breast cancer using genetic information alone and obtained an
AUC of 67% (95% CI= 63.1–70.9%). This represents the best
performance to date using benign breast lesions, despite the
exclusion of subjects with atypical hyperplasia42. Importantly, we
have identified a currently uncatalogued signature, which we have
designated O/TN, that is associated with triple negative breast
cancer (p= 0.007), which was validated in 109 TCGA TNBC
samples (p= 0.001); we found that PIK3CA pH1047R hotspot
mutation is more frequent in proliferative disease without atypia
(PDWA) compared to non-proliferative disease (p < 0.001); we
observed multiple recurrent CNVs as well, including a MLH3
deletion, which is significantly associated with a mismatch repair
signature (p < 0.001).
This study has several strengths and weaknesses. The speci-
mens are richly annotated with clinical information (Supplemen-
tary Data 1)22 and they have been laboriously microdissected in
order to sample the epithelial compartment. The controls have a
long median follow up and were verified not to have been
diagnosed with BC by a telephone interview carried out at the
time of this study. We have leveraged the advantages of machine
learning/artificial intelligence to enable the calling of somatic
mutations in the absence of germline data.
Weaknesses include the relatively small size of the study and
the lack of an independent validation dataset, so that the findings
we report here must be regarded as preliminary until larger
numbers can be studied. We were able to obtain germline
specimens on only 26 subjects. Data from these 26 specimens was
utilized to build the Panel of Normals (PoN) for germline variant
filtering; GATK recommends a minimum of 40. Using less than the
suggested minimum may result in suboptimal denoising of the
data and may not capture all the common germline variants. Since
all subjects consented to participation and to recontact, we are
working actively to acquire additional germline samples. Finally,
the use of formalin-fixed paraffin embedded breast samples,
although unavoidable in this setting, risks introducing artefactual
findings. Among the FFPE artifacts are C to T transitions
hypothesized to be the result of the deamination of cytosines43,44
and both Rohan et al.31 and Soyal et al.41 screened for these
substitutions. However, a large, prospective study carried out by
the 100,000 Genomes Project argues that the choice of mutation
caller as well as tissue heterogeneity or sampling may contribute
to differences between FFPE and frozen tissue45. Our O/TN
signature is not dominated by C to T transitions. Although our
MMR signature and aging signatures are populated by C to T
transitions, we think it unlikely that these are due to formalin-
induced deamination, as our signatures closely mirror those of
WTSI 6 and 1b, respectively, which were derived from frozen
specimens. Considering the risk of ruling out true mutations,
therefore, we did not attempt to account the FFPE artifacts in our
pipeline.
In contrast to our findings, Soysal et. al found no specific
mutations in their study of benign breast lesions. Their depth of
sequencing was more than adequate but only 17 patient samples
were included41, with lesions that they called “fibrocystic breast
disease with or without UDH, FEA, or CCL”. These lesions, with the
exception of flat epithelial atypia, were also included in our study,
making it unlikely that the choice of histology is determinative. We
should consider the possibility that single nucleotide somatic
mutation is not the correct genetic determinant of risk. Single cell
sequencing of synchronous DCIS and invasive ductal carcinomas
has revealed that CNV is early oncogenic event, i.e., present in
in situ lesions, and that no additional CNV events are acquired
during the transition from in situ to invasive lesion46. In a study
separate from the one referred to earlier, Soysal et al. showed that
ESR1 gene amplifications are an early event in breast carcinogen-
esis and are already present, at least in part, in FD47. Additionally,
recurrent CNVs are more characteristic of invasive breast cancers
than are recurrent mutations39. Key breast cancer phenotypes,
including intrinsic molecular subtypes, estrogen receptor status,
and TP53 mutation status as well as proliferative status and
estrogen-signaling pathway activity can be predicted by DNA
copy number features alone48.
Lesions such as hyperplasia, not all of which are obligate
precursors of malignancy, already show evidence of activation of
DNA damage response pathways. This is a response to oncogene-
induced DNA replication stress causing unscheduled S-phase
entry with consequent aberrant replication structures and DNA
damage, which activate ATR/Chk1, ATM/Chk2, and p53, ultimately
preventing progression by arresting growth or triggering cell
death49. Intriguingly, with regard to our data, is the fact that in the
early lesions that are genetically most stable, loss of hetero-
zygosity at known fragile sites is observed to occur 3–15 times
more often than expected from random targeting of these sites49.
Fragile sites were also noted to be targeted during the period in
which DNA damage response is maximal. These data suggest a
model in which oncogene activation is an early event in at-risk
tissue and that cells activate the ATR/ATM-regulated DNA damage
responses that delay or prevent malignant progression. This may
explain why we observe equivalent somatic mutations, e.g. PIK3CA
(H1047R), in cases and controls. The ATR and ETAA1mutations that
we observed in the BBCAR specimens and their matched tumors
may be the specific mutations that enable oncogenic progression
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in the cases. Inactivating mutations including any in the ATM/Chk2
or ATR/Chk1 pathways potentially would remove the barrier to
progression and result in cell proliferation and survival, increasing
genomic instability and tumor progression.
Our O/TN signature is enriched with T > G/A > C mutations, with
5′TTC3′ > 5′TGC3′ the most frequently mutated trinucleotide
motif. These single nucleotide T > G transversions are observed
in vitro when equimolar oxidized dGTP (8-O-dGTP) is included in
the nucleotide pool50. Strand information is lost between the
initial occurrence of a mutagenic lesion and the ultimate readout
by DNA sequencing. Conventionally, mutational signatures are
displayed with a mutated pyrimidine at the center of the
trinucleotide motif. The complement to 5′TTC3′ > 5′TGC3′ is 5′
GAA3′ > 5′GCA3′. There is a 4- to 5-fold difference in the 8-O-dGTP
mutation rate depending on the sequence context with 5′GAA3′
being a favored context50. The nucleotide pool is sanitized by
MTH1, which hydrolyzes cytotoxic oxidized dNTPs, preventing
them from becoming mis-incorporated into DNA during replica-
tion or repair. Even with this cellular sanitizing activity, nucleotide
pools contain enough 8-oxo-dGTP to promote mutagenesis51,52.
Mutagenesis results from the insertion of 8-O-dGTP across from
adenine rather than cytosine during DNA replication. Steric
hindrance of the oxygen of cytosine (C) in the anti-conformation
with the triphosphate group of the 8-oxo-dGTP also in the anti-
conformation prevents Watson-Crick base pairing53. However, 8-
oxo-dGTP can assume the syn conformation enabling Hoogsteen
base pairing with Adenine (A). This A(template): Gox (nascent) base
paring results in T > G/A > C following two additional rounds of
replication53.
The association of triple negative breast cancer (TNBC) with our
O/TN signature is intriguing. About 80% of TNBCs are of the basal-
like subtype54 and this subtype likely originates from luminal
progenitor cells55,56. We hypothesize that the O/TN signature
results from deficient repair of a specific oxidative lesion as
discussed above. The levels of reactive oxygen species and
antioxidant defenses have been assayed in both luminal
progenitor (LP) and basal cells of normal human mammary
tissue57. Higher levels of both superoxide anion and hydrogen
peroxide are present in the LPs. Even though multiple antioxidants
are deployed, LP display higher levels of oxidative damage,
specifically increased incorporation of 8-oxo-deoxyguanosine (8-
oxo-dG) within the genomic DNA. Therefore, the association of
TNBC with our O/TN signature may reflect the susceptibility of its
precursor LP cells to oxidative damage, placing them at a
disadvantage if this damage cannot be adequately addressed
due to mismatch deficiency.
MHL3 deletion was strongly associated with our MMR signature.
The trinucleotide motifs most frequently mutated in our MMR
signature and WTSI Signature 6 are 5′GCG3′ > 5′GTG3′, 5′CCG3′ >
5′CTG3′, 5′ACG3′ > 5′ATG3′. These mutations are hypothesized to
due to an error in the replication of 5-methylcytosine (5mC).
Tomkomva et al. have advanced a model, which posits that
wildtype Pol ε has slightly decreased fidelity when encountering
5mC, particularly in a GCG context, on the template strand and
incorrectly pairs it with A, leading to 5mC:A mismatches58. They
note that there is high structural similarity between 5mC and T,
both of which present a methyl group at the same position of
pyrimidine ring. If the resulting 5mC:A mismatches are not
repaired before the next round of replication due to dysfunctional
mismatch repair, one would expect an enrichment of NCG > NTG
mutations. Given this hypothesized etiology of the mutations, is
there evidence that MHL3 repairs such mutations? Sequencing of
the tumors arising from the cross of Apc1638N mutant mice with
Mhl3 nullizygous and Mlh3-/-; Pms2-/- mice reveals that the C:G > T:
A transition mutations, irrespective of MMR genotypes, occurred
at either CpG dinucleotides or CpNpG sites, typical targets for DNA
methylation59. Thus, although our numbers are small, it appears
that our MMR Signature in the controls may result from MLH3
deletion; as the same signature is observed in the cases another
mechanism of MLH3 silencing may be operative in the cases such
as promoter methylation.
The ten most frequently mutated genes shared between the
BBB of cases and their tumors are given in Supplementary Table 4.
Among them are FAT1, CTNNA2, ATR, and ETAA1. FAT1 has the
most mutations, which is interesting as this same gene was shown
to have a statistically significant excess of inactivating mutations
across all classes in the sun-exposed, physiologically normal
epidermis study17. FAT1 encodes a cadherin-like protein and its
inactivation via mutation may lead to tumorigenesis by multiple
avenues60,61. From a breast cancer standpoint, investigations into
the etiology of CDK4/6 inhibitor resistance have provided
significant clues to FAT1’s role as a tumor suppressor62. Loss of
FAT1 activity results in increased expression of CDK6, consequent
to dysregulation of the Hippo pathway. ATR and ETAA1 have been
discussed earlier regarding their function as barriers to progres-
sion. We hypothesize that the CNV we have observed is due to
replication stress. Replication stress leads to stalled replication
forks and if ATR or ETAA1 mutation renders the proteins unable to
stabilize the forks and allow time for repair, further genomic
instability in the genome is likely to ensue63. ATR also specially
regulates fragile site stability64. While admittedly our number of
matched BBB and tumors is limited, the data from these
specimens suggests that, later in oncogenesis, mutations in ATR
pathway members, i.e., ATR and ETAA1, are being selected for as
they observed in both the benign biopsy and its matched tumor.
We note that ATR haploinsufficieny in a mismatch repair deficient
background has been shown to result in dramatic increases in
fragile site instability, amplifications and rearrangements, and in
decreased tumor latency65.
In summary, we have taken an initial step towards what will be
a series of investigations of somatic DNA changes in the
unaffected breast, which will help define alterations that put
women at substantially elevated BC risk. Such studies will also
provide the possibility of estimating the time frame of that risk, so
that women are able to make practical decisions regarding the
interventions that they choose to adopt. We have shown that such
work is feasible, with sequencing quality that meets current
standards in the field, that somatic sequencing data can be
inferred and interpreted even in the absence of matched germline




At the Northwestern Feinberg School of Medicine, we designed a case-
control study of BBB samples (BBCAR Study)66. Subjects were identified
through searches of the Enterprise Data Warehouse of Northwestern
Medicine (NM), and at the Lynn Sage Breast Center of NM, under IRB-
approved protocol NU 09B2. The major eligibility criterion required a
history of benign breast biopsy performed at NM, at least 1 year prior to
cancer diagnosis for cases. Eligible subjects provided written informed
consent for the use of their BBB blocks after the nature and possible
consequences of the study were explained, and completed a survey
detailing breast history and breast cancer risk factors. We have retrieved
the BBB paraffin blocks of subjects who subsequently developed breast
cancer (cases) and from age-matched controls, who have not developed
breast cancer to date. The participants are contacted periodically to
confirm that controls have not transitioned to cases. A subset of 135 cases,
matched to 69 controls were selected for WES (“Supplementary Materials
and Methods”). All subjects included in this analysis were of European
descent. Case and control samples are matched by age and histologic class
(non-proliferative benign change, or proliferation without atypia). DNA was
isolated from the LCM epithelium and sequenced using the Illumina
HiSeq4000. WES was conducted with a sequencing depth of 80–100× and
80–90 million sequencing reads were generated for each sample
(Supplementary Materials and Methods).
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Parallel alignment of whole-exome analysis
We adapted widely used open source software for genome alignment and
variant calling. Read alignment and variant calling were performed
according to the Broad Institute’s Genome Analysis Toolkit (GATK) best
practices pipeline67. Reads were aligned to the human reference genome
(hg19) using Burrows-Wheeler alignment68 and Picard 2.6 was subse-
quently used to sort reads and mark duplicates (Fig. 1c). To reduce
systematic errors, sorted BAM files were separately generated based on the
sequence lane that the reads were generated. By doing so, various
technical artifacts that are associated with lane-specific artifacts can be
removed during duplicate marking and base recalibration steps. Base
recalibration was done using the GATK 3.6 using dbSNP build 138 as a
training set. Mutations were called and filtered using MuTect2 in the GATK
package. To capture recurrent technical artifacts, we generated a Panel of
Normals (PON) for Mutect2 analysis using the sequenced 26 germline DNA.
The PON is created by running the variant caller Mutect2 individually on
the normal samples and combining the resulting variant calls with the
criteria of excluding any sites that are not present in at least 2 normals,
which is the default cutoff69. For the samples without matched normal
DNA available, we run Mutect2 using the so called “tumor only” model
with PON filtering to call mutations. To obtain a set of mutations with the
highest sensitivity, VarScan235 and VarDict70 were also applied for
mutation calling. To further ensure a high precision call rate, we filtered
all mutations with read depth <20. After filtering, mutations were then
annotated using SNPEFF71, VEP72, and ANNOVAR25.
Somatic mutation identification
Our initial objective was to develop and test a predictive model for somatic
mutation identification. A significant challenge for this study, and for
others seeking to identify somatic mutations in archived tissue samples is
the lack of matched germline DNA. Therefore, to prepare for ground truth,
previously consented donors were re-contacted (with IRB approval) and
saliva specimens were requested for normal DNA sequencing. Matched
germline DNA was obtained for 26 of the 204 BBB specimens which had
been selected for WES. For these 26 paired samples, a set of somatic
mutations were generated by using Mutect2 tumor-normal pair mode with
PON filtering. Independently, for these BBB samples, a set of mutations
were generated using Mutect2 tumor-only mode with PON filtering. This is
the mode to be used for the rest of BBBs without matched normal DNA.
However, mutations generated in this mode contain germlines variants. To
rule these germline variants, we overlapped this set mutations with their
BBB’s germline variants, which were generated using GATK Haplotype
callers. The overlapped variants were then labeled as germline variants,
together with the somatic mutations were used for model evaluation. We
systematically evaluated multiple machine learning models and adopted
Multi-Layer Perceptron (MLP) for somatic mutation classification. Features
in the prediction model included intrinsic sequencing features, such as
mutation allele frequency, depth of reference reads, number of
appearances in the cohort as well as published collated data providing
the frequency of the variant in the population and predictions of the
impact of amino acid changes on the structure and function of the
encoded protein. The model obtained an accuracy of 95% for somatic
mutation in the test set (“Supplementary Materials and Methods”).
Orthogonal SNP array genotyping was performed to compare and validate
the performance of mutation calling and mutation classification. Technical
validation was performed for 17 of the 26 specimens for which matched
germline data was available, and 3 of the specimens without matched
germline, using the Infinium Exome-24 v1.1 beadchip (“Supplementary
Materials and Methods”). The case group is defined as benign biopsies that
developed breast cancer at least one year later after the biopsy. In the case
group, we have retrieved 10 cancer blocks that matched to the cases
(Fig. 1b). The same preprocessing procedures were performed as benign
biopsies, including LCM dissection, DNA extraction, library construction,
sequencing, alignment, mutation calling, and filtering.
Somatic copy number variation and mutational signature
Using both aligned reads and identified mutations, we studied the genetic
aberrations that distinguish cases from controls, including mutations and
CNVs. We identified the somatic mutations or CNVs that were common to
both the cases’ benign biopsy tissue as well as paired malignant lesions for
the ten cases in which we had both tissues available. P-values were derived
with the use of Chi-square test or logistic regression. We also studied the
mutations to enable the discovery of mutational signatures. Lastly, we
evaluated machine learning models and features for breast cancer risk
prediction for the cohort. Benjamini-Hochberg method was applied to
convert the two-sided P-values to False Discover Rate (FDR) for multi-
comparison correction.
A Mutational Signature study was performed to reveal underlying
mutational processes for cancer development. The identified somatic
mutations were presented as a 96-element vector, which captures the
immediate 5′ and 3′ neighbors of the mutated nucleotides. The summary
of these mutation characteristics forms a mutational profile for each tissue
sample. Putting multiple samples’ profiles together form a matrix with the
number of samples as rows (204) and the mutation characteristics as
columns (96). Nonnegative matrix factorization (NMF) was applied to
enable the discovery of intrinsic patterns in this matrix. The first value
where the Residual Sum of Squares (RSS) curve presents an inflection point
was used to determine the number of signatures. In total, three signatures
were discovered among the cases and controls, or combined. The outputs
of NMF consist of an H matrix and a W matrix. The matrix H (dimension of
3 × 96) was used to infer mutational processes. The numbers in matrix W
(dimension of 204 × 3) correspond to each samples’ signature exposure
levels. This matrix was interpreted as each tissue sample’s accumulated
exposure effect to the mutational burden. We further evaluated the
association between the signature exposure level and cancer development
with logistic regressions, adjusting for age and histology class.
Cancer risk prediction at BBB
To predict cancer development using the mutations identified in BBB, we
fit logistic regression with L1 penalty using the case/control status as
output variable. Multiple input features have been tested, namely, clinical
risk factors, somatic mutations, mutation burden by gene/cytoband/
protein domain. The mutation burden is inferred by aggregating all
somatic mutations annotated as same gene/cytoband/protein domain to a
continuous number, representing the mutation burden of the correspond-
ing unit. In a cross-comparison evaluation, we achieved the best results
using protein domains as aggregation unit. In total, 1966 annotated
protein domains were utilized as input features for case/control prediction
(Supplementary data 5)22. To evaluate the model and features, we
performed a bootstrapping by randomly splitting the BBB samples at a 7:3
ratio for training and testing. We also evaluated the models by including
clinical risk factors, including age at the time of BBB, age at menarche, age
at first live birth, family history of BC in a first-degree relative, histologic
variable (proliferative vs non-proliferative).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The datasets generated and analysed during the current study are publicly available
in the figshare repository: https://doi.org/10.6084/m9.figshare.1219179322. Whole-
exome sequencing data, generated during the current study, are publicly available in
NCBI Sequence Read Archive (SRA) here: https://identifiers.org/insdc.sra:SRP21932823.
TCGA data supporting Fig. 2, were downloaded from the Genomic Data Commons
(GDC) data portal, though a dbGaP application. The link to the relevant dbGaP study
is https://identifiers.org/dbgap:phs000178.v1.p1.
CODE AVAILABILITY
All codes necessary to process the sequencing data and to re-generate the results are
publicly available at https://github.com/zexian/BBCAR_codes22.
Received: 16 September 2019; Accepted: 8 May 2020;
REFERENCES
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA: a cancer J. clinicians
69, 7–34 (2019).
2. Flanagan, M. R., et al. Chemoprevention Uptake for Breast Cancer Risk Reduction
Varies by Risk Factor. Ann. Surg. Oncol. https://doi.org/10.1245/s10434-019-07236-8
(2019).
Z. Zeng et al.
9
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2020)    24 
3. Gail, M. H. et al. Projecting individualized probabilities of developing breast
cancer for white females who are being examined annually. J. Natl Cancer Inst.
81, 1879–1886 (1989).
4. Chlebowski, R. T. et al. Predicting risk of breast cancer in postmenopausal women
by hormone receptor status. J. Natl Cancer Inst. 99, 1695–1705 (2007).
5. Pankratz, V. S. et al. Assessment of the accuracy of the Gail model in women with
atypical hyperplasia. J. Clin. Oncol. 26, 5374–5379 (2008).
6. Boughey, J. C. et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer
Intervention Study) model for breast cancer risk prediction in women with aty-
pical hyperplasia. J. Clin. Oncol. 28, 3591–3596 (2010).
7. Dupont, W. D. & Page, D. L. Risk factors for breast cancer in women with pro-
liferative breast disease. N. Engl. J. Med. 312, 146–151 (1985).
8. Dupont, W. D. et al. Breast cancer risk associated with proliferative breast disease
and atypical hyperplasia. Cancer 71, 1258–1265 (1993).
9. Visscher, D. W. et al. Clinicopathologic features of breast cancers that develop in
women with previous benign breast disease. Cancer 122, 378–385 (2016).
10. Silverstein, M. J. et al. Special report: consensus conference III. Image-detected
breast cancer: state-of-the-art diagnosis and treatment. J. Am. Coll. Surg. 209,
504–520 (2009).
11. Ju, Y. S. et al. Somatic mutations reveal asymmetric cellular dynamics in the early
human embryo. Nature 543, 714–718 (2017).
12. Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells.
Nat. Genet 47, 1402–1407 (2015).
13. Knudson, A. G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1,
157–162 (2001).
14. Tamborero, D. et al. Comprehensive identification of mutational cancer driver
genes across 12 tumor types. Sci. Rep. 3, 2650 (2013).
15. Danforth, D. N. Jr. Genomic changes in normal breast tissue in women at normal
risk or at high risk for breast cancer. Breast Cancer (Auckl.) 10, 109–146 (2016).
16. Sakr, R. A. et al. Targeted capture massively parallel sequencing analysis of LCIS
and invasive lobular cancer: repertoire of somatic genetic alterations and clonal
relationships. Mol. Oncol. 10, 360–370 (2016).
17. Martincorena, I. et al. High burden and pervasive positive selection of somatic
mutations in normal human skin. Science 348, 880–886 (2015).
18. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458,
719–724 (2009).
19. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer.
Nature 500, 415–421 (2013).
20. Temko, D., Tomlinson, I. P. M., Severini, S., Schuster-Bockler, B. & Graham, T. A. The
effects of mutational processes and selection on driver mutations across cancer
types. Nat. Commun. 9, 1857 (2018).
21. Hartmann, L. C. et al. Benign breast disease and the risk of breast cancer. N. Engl.
J. Med. 353, 229–237 (2005).
22. Zeng, Z., et al. Datasets and metadata supporting the published article: somatic
genetic aberrations in benign breast disease and the risk of subsequent breast
cancer. figshare. https://doi.org/10.6084/m6089.figshare.12191793 (2020).
23. NCBI Sequence Read Archive https://identifiers.org/insdc.sra:SRP219328 (2020).
24. Flanagan, S. E., Patch, A.-M. & Ellard, S. Using SIFT and PolyPhen to predict loss-of-
function and gain-of-function mutations. Genet. Test. Mol. Biomark. 14, 533–537
(2010).
25. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
26. Kalatskaya, I. et al. ISOWN: accurate somatic mutation identification in the
absence of normal tissue controls. Genome Med. 9, 59 (2017).
27. Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and
mutations. Cell 173, 371–385.e318 (2018).
28. Sharma, Y. et al. A pan-cancer analysis of synonymous mutations. Nat. Commun.
10, 2569 (2019).
29. Pearlman, R. et al. Prevalence and spectrum of germline cancer susceptibility
gene mutations among patients with early-onset colorectal cancer. JAMA Oncol.
3, 464–471 (2017).
30. Hanisch, F. G. O-glycosylation of the mucin type. Biol. Chem. 382, 143–149 (2001).
31. Rohan, T. E. et al. Somatic mutations in benign breast disease tissue and risk of
subsequent invasive breast cancer. Br. J. Cancer 118, 1662–1664 (2018).
32. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-
genome sequences. Nature 534, 47–54 (2016).
33. Petljak, M. et al. Characterizing mutational signatures in human cancer cell lines
reveals episodic APOBEC mutagenesis. Cell 176, 1282–1294.e1220 (2019).
34. Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is
widespread in human cancers. Nat. Genet 45, 970–976 (2013).
35. Koboldt, D. C., et al. VarScan 2: somatic mutation and copy number alteration
discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
36. Mermel, C. H. et al. GISTIC2. 0 facilitates sensitive and confident localization of the
targets of focal somatic copy-number alteration in human cancers. Genome Biol.
12, R41 (2011).
37. Bass, T. E. et al. ETAA1 acts at stalled replication forks to maintain genome
integrity. Nat. Cell Biol. 18, 1185–1195 (2016).
38. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature 486, 346–352 (2012).
39. Ciriello, G. et al. Emerging landscape of oncogenic signatures across human
cancers. Nat. Genet. 45, 1127–1133 (2013).
40. Davies, H. et al. Whole-genome sequencing reveals breast cancers with mismatch
repair deficiency. Cancer Res 77, 4755–4762 (2017).
41. Soysal, S. D. et al. Genetic alterations in benign breast biopsies of subsequent
breast cancer patients. Front Med. (Lausanne) 6, 166 (2019).
42. Pankratz, V. S. et al. Model for individualized prediction of breast cancer risk after
a benign breast biopsy. J. Clin. Oncol. 33, 923–929 (2015).
43. Spencer, D. H. et al. Comparison of clinical targeted next-generation sequence
data from formalin-fixed and fresh-frozen tissue specimens. J. Mol. Diagn. 15,
623–633 (2013).
44. Bhagwate, A. V. et al. Bioinformatics and DNA-extraction strategies to reliably
detect genetic variants from FFPE breast tissue samples. BMC Genomics 20, 689
(2019).
45. Robbe, P. et al. Clinical whole-genome sequencing from routine formalin-fixed,
paraffin-embedded specimens: pilot study for the 100,000 Genomes Project.
Genet Med. 20, 1196–1205 (2018).
46. Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus
genome sequencing. Nature 512, 155–160 (2014).
47. Soysal, S. D. et al. Status of estrogen receptor 1 (ESR1) gene in mastopathy
predicts subsequent development of breast cancer. Breast Cancer Res Treat. 151,
709–715 (2015).
48. Xia, Y., Fan, C., Hoadley, K. A., Parker, J. S. & Perou, C. M. Genetic determinants of
the molecular portraits of epithelial cancers. Nat. Commun. 10, 5666 (2019).
49. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis
barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).
50. Minnick, D. T., Pavlov, Y. I. & Kunkel, T. A. The fidelity of the human leading and
lagging strand DNA replication apparatus with 8-oxodeoxyguanosine tripho-
sphate. Nucleic Acids Res 22, 5658–5664 (1994).
51. Colussi, C. et al. The mammalian mismatch repair pathway removes DNA 8-
oxodGMP incorporated from the oxidized dNTP pool. Curr. Biol. 12, 912–918
(2002).
52. Pursell, Z. F., McDonald, J. T., Mathews, C. K. & Kunkel, T. A. Trace amounts of 8-
oxo-dGTP in mitochondrial dNTP pools reduce DNA polymerase gamma repli-
cation fidelity. Nucleic Acids Res 36, 2174–2181 (2008).
53. Freudenthal, B. D. et al. Uncovering the polymerase-induced cytotoxicity of an
oxidized nucleotide. Nature 517, 635–639 (2015).
54. Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into molecular classifications
of triple-negative breast cancer: improving patient selection for treatment.
Cancer Disco. 9, 176–198 (2019).
55. Lim, E. et al. Aberrant luminal progenitors as the candidate target population for
basal tumor development in BRCA1 mutation carriers. Nat. Med 15, 907–913 (2009).
56. Molyneux, G. et al. BRCA1 basal-like breast cancers originate from luminal epi-
thelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403–417 (2010).
57. Kannan, N. et al. Glutathione-dependent and -independent oxidative stress-
control mechanisms distinguish normal human mammary epithelial cell subsets.
Proc. Natl Acad. Sci. USA 111, 7789–7794 (2014).
58. Tomkova, M., McClellan, M., Kriaucionis, S. & Schuster-Bockler, B. DNA Replication
and associated repair pathways are involved in the mutagenesis of methylated
cytosine. DNA Repair (Amst.) 62, 1–7 (2018).
59. Chen, P. C. et al. Novel roles for MLH3 deficiency and TLE6-like amplification in
DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression.
PLoS Genet 4, e1000092 (2008).
60. Morris, L. G. et al. Recurrent somatic mutation of FAT1 in multiple human cancers
leads to aberrant Wnt activation. Nat. Genet 45, 253–261 (2013).
61. Martin, D. et al. Assembly and activation of the Hippo signalome by FAT1 tumor
suppressor. Nat. Commun. 9, 2372 (2018).
62. Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6
inhibitors via the hippo pathway. Cancer Cell 34, 893–905.e898 (2018).
63. Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat.
Rev. Mol. Cell Biol. 9, 616–627 (2008).
64. Casper, A. M., Nghiem, P., Arlt, M. F. & Glover, T. W. ATR regulates fragile site
stability. Cell 111, 779–789 (2002).
65. Fang, Y. et al. ATR functions as a gene dosage-dependent tumor suppressor on a
mismatch repair-deficient background. EMBO J. 23, 3164–3174 (2004).
66. Shidfar, A. et al. Expression of miR-18a and miR-210 in normal breast tissue as
candidate biomarkers of breast cancer risk. Cancer Prev. Res. (Phila.) 10, 89–97
(2017).
67. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for
analyzing next-generation DNA sequencing data. Genome Res 20, 1297–1303
(2010).
Z. Zeng et al.
10
npj Breast Cancer (2020)    24 Published in partnership with the Breast Cancer Research Foundation
68. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler
transform. Bioinformatics 26, 589–595 (2010).
69. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and
heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
70. Lai, Z. et al. VarDict: a novel and versatile variant caller for next-generation
sequencing in cancer research. Nucleic acids Res. 44, e108 (2016).
71. Cingolani, P. et al. A program for annotating and predicting the effects of single
nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melano-
gaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80–92 (2012).
72. McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122
(2016).
ACKNOWLEDGEMENTS
We thank the Center for Medical Genomics at the Indiana University School of
Medicine for the library preparation and high throughput sequencing. This study was
supported in part by Breast Cancer Research Foundation, the Lynn Sage Cancer
Research Foundation, and grant R21LM012618-01 from the National Institutes of
Health.
AUTHOR CONTRIBUTIONS
Z.Z., S.A.K., and S.E.C. conceived the study. A.S. performed laser capture microdisse-
cion and extracted the DNA. P.S. administered the questionnaires, organized the
clinical data, and contacted the subjects for saliva donation and cancer status
confirmation. X.X. performed the sequencing. L.B. reviewed all benign biopsy and
tumor sections, verified histologic diagnosis, and identified areas for laser capture.
Z.Z. and A.V. carried out the sequence alignment, quality assessment, and mutation
calling. S.E.C. and Z.Z. wrote the paper. Z.Z. and X.L. performed the statistical analysis.
Y.L. reviewed all analyzed data. S.A.K. was responsible for the clinical study. All
authors discussed the results, revised and approved the paper.
COMPETING INTERESTS
The authors declare no competing interests.
ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/
s41523-020-0165-z.
Correspondence and requests for materials should be addressed to Y.L., S.A.K. or S.E.C.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2020
Z. Zeng et al.
11
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2020)    24 
